These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33396548)

  • 1. The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia.
    Samadzadeh S; Brauns R; Hefter H
    Toxins (Basel); 2020 Dec; 13(1):. PubMed ID: 33396548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.
    Dressler D; Bigalke H; Benecke R
    J Neurol; 2003 Aug; 250(8):967-9. PubMed ID: 12928917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia.
    Hefter H; Schomaecker I; Schomaecker M; Rosenthal D; Samadzadeh S
    Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of dose and response to botulinum toxin A in cervical dystonia: a multicenter study.
    Ruiz PJ; Castrillo JC; Burguera JA; Campos V; Castro A; Cancho E; Chacón J; Vara JH; del Val JL; Garcia EL; Miquel F; Sanz P; Vela L
    J Neurol; 2011 Jun; 258(6):1055-7. PubMed ID: 21197540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical utility of botulinum toxin injections targeted at the motor endplate zone in cervical dystonia.
    Delnooz CC; Veugen LC; Pasman JW; Lapatki BG; van Dijk JP; van de Warrenburg BP
    Eur J Neurol; 2014 Dec; 21(12):1486-e98. PubMed ID: 25060697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin.
    Misra VP; Colosimo C; Charles D; Chung TM; Maisonobe P; Om S;
    J Neurol; 2018 Feb; 265(2):402-409. PubMed ID: 29270685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Pseudo"-Secondary Treatment Failure Explained via Disease Progression and Effective Botulinum Toxin Therapy: A Pilot Simulation Study.
    Hefter H; Rosenthal D; Samadzadeh S
    Toxins (Basel); 2023 Oct; 15(10):. PubMed ID: 37888649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis.
    Hefter H; Spiess C; Rosenthal D
    J Neural Transm (Vienna); 2014 May; 121(5):513-9. PubMed ID: 24311063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
    Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
    Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA.
    Hefter H; Samadzadeh S; Moll M
    Toxins (Basel); 2020 Oct; 12(11):. PubMed ID: 33121133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons about Botulinum Toxin A Therapy from Cervical Dystonia Patients Drawing the Course of Disease: A Pilot Study.
    Hefter H; Schomaecker I; Schomaecker M; Ürer B; Brauns R; Rosenthal D; Albrecht P; Samadzadeh S
    Toxins (Basel); 2023 Jun; 15(7):. PubMed ID: 37505701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
    Pappert EJ; Germanson T;
    Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation-A Monocentric Cross-Sectional Pilot Study.
    Hefter H; Schomaecker I; Schomaecker M; Rosenthal D; Samadzadeh S
    Medicina (Kaunas); 2022 Jan; 58(1):. PubMed ID: 35056396
    [No Abstract]   [Full Text] [Related]  

  • 14. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B.
    Oshima M; Deitiker PR; Jankovic J; Duane DD; Aoki KR; Atassi MZ
    J Neuroimmunol; 2011 Dec; 240-241():121-8. PubMed ID: 22079193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia.
    Brashear A; Hogan P; Wooten-Watts M; Marchetti A; Magar R; Martin J
    Adv Ther; 2005; 22(1):49-55. PubMed ID: 15943222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy.
    Walter U; Mühlenhoff C; Benecke R; Dressler D; Mix E; Alt J; Wittstock M; Dudesek A; Storch A; Kamm C
    Neurology; 2020 May; 94(20):e2109-e2120. PubMed ID: 32332130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure.
    Hefter H; Ürer B; Brauns R; Rosenthal D; Meuth SG; Lee JI; Albrecht P; Samadzadeh S
    Toxins (Basel); 2022 Jan; 14(1):. PubMed ID: 35051021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal.
    Marsili L; Bologna M; Jankovic J; Colosimo C
    Expert Opin Drug Saf; 2021 Jun; 20(6):695-705. PubMed ID: 33831328
    [No Abstract]   [Full Text] [Related]  

  • 19. The impact of the initial severity on later outcome: retrospective analysis of a large cohort of botulinum toxin naïve patients with idiopathic cervical dystonia.
    Hefter H; Samadzazeh S; Rosenthal D
    J Neurol; 2021 Jan; 268(1):206-213. PubMed ID: 32761340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.
    Albrecht P; Jansen A; Lee JI; Moll M; Ringelstein M; Rosenthal D; Bigalke H; Aktas O; Hartung HP; Hefter H
    Neurology; 2019 Jan; 92(1):e48-e54. PubMed ID: 30464031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.